pharma · Acute Myeloid Leukemia · Acute Leukemia · ATNM
Actinium Pharmaceuticals
Actinium Pharmaceuticals is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker ATNM. Primary therapeutic focus areas include Acute Myeloid Leukemia, Acute Leukemia, Sickling Disorder Due
New York, USA HQ
2000 Founded
58 Employees
Public company Type
ATNM · NYSE Ticker
Company details
- Status
- Public
- HQ
- New York, USA
- Founded
- 2000
- Employees
- 58
- Programs
- 8
- Drugs
- 4
- Patents
- 20
Iomab-B
Phase 2 · small molecule · Non Hodgkin Lymphoma
Iomab-B for Non Hodgkin Lymphoma is a Phase 2 program (small_molecule) at Actinium Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code STU-2024-1091; SCCC-03424
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Actinium Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Non Hodgkin Lymphoma
- Status
- active
- Trials
- 1